Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acorda Therapeutics, Inc.ACOR · Entity 111987 | Director | June 22, 2023 | June 23, 2023 |
| Aravive, Inc.VSAR · Entity 114535 | Director | December 20, 2017 | December 22, 2017 |
| SELLAS Life Sciences Group, Inc.SLS · Entity 4313 | Director | January 07, 2026 | January 09, 2026 |
| XOMA Royalty CorpXOMA · Entity 30207 | Director | February 10, 2017 | May 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acorda Therapeutics, Inc.
Report date June 22, 2023 · Filed June 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $12.99 · Expires 2033-06-22 | Direct | 1,200 |
Reported balance
After 2023-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-22 · Grant · Acquired 1,200 · Balance 1,200 F1: Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 22, 2023, with the first quarterly installment vesting on September 22, 2023, subject to continued service on the company's Board of Directors through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 22, 2023, with the first quarterly installment vesting on September 22, 2023, subject to continued service on the company's Board of Directors through each vesting date.
Aravive, Inc.
Report date December 20, 2017 · Filed December 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,280 |
Reported balance
After 2017-12-20 transaction · row 1
1 source rowRow 1 · 2017-12-20 · Grant · Acquired 11,200 · Balance 22,280 F1: Represents the grant of restricted stock units that vest 100% on December 20, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest 100% on December 20, 2018.
SELLAS Life Sciences Group, Inc.
Report date January 07, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 72,900 |
Reported balance
After 2026-01-07 transaction · row 1
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 50,000 · Balance 72,900 F1: The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.
XOMA Royalty Corp
Report date February 10, 2017 · Filed May 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.03 · Expires 2027-02-10 | Direct | 8,000 |
Reported balance
After 2017-02-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-10 · Grant · Acquired 8,000 · Balance 8,000 F1: This option was approved by the Board of Directors of the Issuer on February 10, 2017, subject to approval by the Issuer's stockholders, at the 2017 Annual Meeting of Stockholders, of an amendment of the Issuer's 2010 Long Term Incentive and Stock Award Plan (the "Plan"), including an increase in the number of shares reserved for issuance under the Plan (the "Amendment"). The Stockholders of the Issuer approved the Amendment on May 18, 2017. F2: Shares subject to this option shall vest in equal monthly installments over three years from the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was approved by the Board of Directors of the Issuer on February 10, 2017, subject to approval by the Issuer's stockholders, at the 2017 Annual Meeting of Stockholders, of an amendment of the Issuer's 2010 Long Term Incentive and Stock Award Plan (the "Plan"), including an increase in the number of shares reserved for issuance under the Plan (the "Amendment"). The Stockholders of the Issuer approved the Amendment on May 18, 2017.
F2: Shares subject to this option shall vest in equal monthly installments over three years from the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Zyla Life Sciences
Report date January 31, 2019 · Filed February 04, 2019
Section 16 reporting ended · disclosed 2019-02-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 · Expires 2028-07-02 | Direct | 0 |
Reported balance
After 2019-01-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-31 · Disposition to issuer · Disposed 110,000 · Balance 0 F1: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 07, 2026 Filed Jan 9, 2026 16:43 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-002515 · tm262627-7_4seq1.xml · nonDerivative · entry 1 Varian John · CIK 0001416176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,900 F1 · shares: The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 17:30 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001104659-25-003495 · tm253166-2_4seq1.xml · derivative · entry 2 Varian John · CIK 0001416176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2035-01-10 F2 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) January 10, 2026 (the first anniversary of the date of grant) or (y) the business day prior to the 2026 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 17:30 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-003495 · tm253166-2_4seq1.xml · nonDerivative · entry 1 Varian John · CIK 0001416176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,900 F1 · shares: The Reporting Person received an award of 12,500 restricted stock units on January 10, 2025, which shall vest in full on December 1, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| January 22, 2024 Filed Jan 25, 2024 06:01 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001104659-24-006392 · tm243935-7_4seq1.xml · derivative · entry 2 Varian John · CIK 0001416176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-01-22 F2 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) January 22, 2025 (the first anniversary of the date of grant) or (y) the business day prior to the 2025 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| January 22, 2024 Filed Jan 25, 2024 06:01 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-006392 · tm243935-7_4seq1.xml · nonDerivative · entry 1 Varian John · CIK 0001416176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,400 F1 · shares: The Reporting Person received an award of 6,000 restricted stock units on January 22, 2024, which shall vest in full on December 1, 2024, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 17:38 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantNon-Employee Stock Option · Derivative | 1,200 | $0.00 Strike: $12.99 | $0.00 |
DisclosureSEC source: 0001209191-23-039483 · doc4.xml · derivative · entry 1 Varian John · CIK 0001416176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,200 Underlying: Common Stock · 1,200 shares Expires 2033-06-22 F1 · derivative.exercise_date: Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 22, 2023, with the first quarterly installment vesting on September 22, 2023, subject to continued service on the company's Board of Directors through each vesting date. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 17:14 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 9,500 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0001104659-23-010635 · tm235353d5_4seq1.xml · derivative · entry 2 Varian John · CIK 0001416176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2033-02-02 F2 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) February 2, 2024 (the first anniversary of the date of grant) or (y) the business day prior to the 2024 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 17:14 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-010635 · tm235353d5_4seq1.xml · nonDerivative · entry 1 Varian John · CIK 0001416176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 F1 · shares: The Reporting Person received an award of 2,500 restricted stock units on February 2, 2023, which shall vest in full on December 1, 2023, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 07:56 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantNon-Employee Stock Option · Derivative | 4,712 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001209191-23-000518 · doc4.xml · derivative · entry 1 Varian John · CIK 0001416176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,712 Underlying: Common Stock · 4,712 shares Expires 2033-01-01 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments over 12 months with the first quarterly installment vesting on April 1, 2023. Read SEC document |
| January 31, 2022 Filed Feb 1, 2022 17:06 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 7,125 | $0.00 Strike: $5.34 | $0.00 |
DisclosureSEC source: 0001104659-22-010399 · tm225088-5_4seq1.xml · derivative · entry 2 Varian John · CIK 0001416176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,125 Underlying: Common Stock · 7,125 shares Expires 2032-01-31 F2 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) January 31, 2023 (the first anniversary of the date of grant) or (y) the business day prior to the 2023 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| January 31, 2022 Filed Feb 1, 2022 17:06 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 1,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-010399 · tm225088-5_4seq1.xml · nonDerivative · entry 1 Varian John · CIK 0001416176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 F1 · shares: The Reporting Person received an award of 1,900 restricted stock units on January 31, 2022, which shall vest in full on December 1, 2022, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 16:22 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantNon-Employee Stock Option · Derivative | 20,000 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001209191-22-000750 · doc4.xml · derivative · entry 1 Varian John · CIK 0001416176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-01-01 F1 · derivative.exercise_date: Option issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in four equal quarterly installments over 12 months with the first quarterly installment vesting on April 1, 2022. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 16:29 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001104659-21-033300 · tm218923d6_4.xml · derivative · entry 1 Varian John · CIK 0001416176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-03-04 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) March 4, 2022 (the first anniversary of the date of grant) or (y) the business day prior to the 2022 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 21:19 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001104659-20-034289 · tm2012902-5_form4.xml · derivative · entry 1 Varian John · CIK 0001416176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2030-03-12 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) March 12, 2021 (the first anniversary of the date of grant) or (y) the business day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 19:02 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0000899243-19-008198 · doc4.xml · derivative · entry 1 Varian John · CIK 0001416176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-03-14 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) March 14, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 20:09 UTC | Zyla Life Sciences EGLT · Entity 148990 | Disposition to issuerStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001179110-19-001263 · edgar.xml · derivative · entry 1 Varian John · CIK 0001416176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,000 shares Expires 2028-07-02 F1 · price: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. F1 · derivative.exercise_date: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. Read SEC document |
| July 02, 2018 Filed Jul 2, 2018 16:48 UTC | Zyla Life Sciences EGLT · Entity 148990 | GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001179110-18-009210 · edgar.xml · derivative · entry 1 Varian John · CIK 0001416176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2028-07-02 F1 · derivative.exercise_date: The option vests with respect to one-fourth of the underlying shares on each of the first four anniversaries of the grant date. Read SEC document |
| June 12, 2018 Filed Jun 13, 2018 18:33 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 5,500 | $0.00 Strike: $5.23 | $0.00 |
DisclosureSEC source: 0001209191-18-037554 · doc4.xml · derivative · entry 1 Varian John · CIK 0001416176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2028-06-11 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) June 12, 2019 (the first anniversary of the date of grant) or (y) the day prior to the 2019 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:02 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $5.24 | $0.00 |
DisclosureSEC source: 0001209191-18-020020 · doc4.xml · derivative · entry 1 Varian John · CIK 0001416176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2028-03-12 F1 · derivative.exercise_date: The option shares will vest and became exercisable in equal monthly installments for thirty-six (36) months following the March 13, 2018 grant date, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 17:13 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantCommon Stock | 11,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-067113 · doc4.xml · nonDerivative · entry 1 Varian John · CIK 0001416176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,280 F1 · shares: Represents the grant of restricted stock units that vest 100% on December 20, 2018. Read SEC document |
| May 25, 2017 Filed Jun 6, 2017 19:57 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantStock Option (Right to Buy) · Derivative | 6,850 | $0.00 Strike: $15.83 | $0.00 |
DisclosureSEC source: 0001209191-17-038229 · doc4.xml · derivative · entry 2 Varian John · CIK 0001416176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,850 Underlying: Common Stock · 6,850 shares Expires 2027-05-24 F2 · derivative.exercise_date: The shares shall vest fully on the earlier of (a) the next annual stockholder meeting held after May 25, 2017 and (b) May 25, 2018. Read SEC document |
| May 25, 2017 Filed Jun 6, 2017 19:57 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantCommon Stock | 3,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038229 · doc4.xml · nonDerivative · entry 1 Varian John · CIK 0001416176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,080 F1 · shares: Represents the grant of restricted stock units that vest fully on the earlier of (a) the next annual stockholder meeting held after May 25, 2017 and (b) May 25, 2018. Read SEC document |
| May 16, 2017 Filed May 18, 2017 19:02 UTC | XOMA Royalty Corp XOMA · Entity 30207 | SaleCommon Shares | 39,540 | $6.24 | $246,919.39 |
DisclosureSEC source: 0000791908-17-000015 · edgardoc.xml · nonDerivative · entry 1 Varian John · CIK 0001416176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,344 F1 · price: The shares were sold at various prices ranging from $6.20 and $6.38. Read SEC document |
| February 10, 2017 Filed May 22, 2017 22:43 UTC | XOMA Royalty Corp XOMA · Entity 30207 | GrantNon-Qualified Share Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0000791908-17-000027 · edgardoc.xml · derivative · entry 1 Varian John · CIK 0001416176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Shares · 8,000 shares Expires 2027-02-10 F1 · date: This option was approved by the Board of Directors of the Issuer on February 10, 2017, subject to approval by the Issuer's stockholders, at the 2017 Annual Meeting of Stockholders, of an amendment of the Issuer's 2010 Long Term Incentive and Stock Award Plan (the "Plan"), including an increase in the number of shares reserved for issuance under the Plan (the "Amendment"). The Stockholders of the Issuer approved the Amendment on May 18, 2017. F2 · derivative.exercise_date: Shares subject to this option shall vest in equal monthly installments over three years from the grant date. Read SEC document |
| December 21, 2016 Filed Dec 23, 2016 23:38 UTC | XOMA Royalty Corp XOMA · Entity 30207 | SaleCommon Shares | 13,549 | $5.75 | $77,906.75 |
DisclosureSEC source: 0000791908-16-000182 · edgardoc.xml · nonDerivative · entry 1 Varian John · CIK 0001416176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,884 F1 · kind: Shares sold on the open market to satisfy the taxes required to be withheld in connection with the vesting of the shares in a non-discretionary transaction pursuant to the reporting person's agreement under the Company's incentive plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.